NCT00671489CompletedPhase 1
Phase 2 Study of Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-01 Study
Japan Science and Technology Agency2 sites in 1 country15 target enrollmentStarted: May 1, 2008Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 15
- Locations
- 2
- Primary Endpoint
- Total score of Clinician-Administrated PTSD Scale (CAPS)
Study Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Polyunsaturated Fatty Acid for the prevention of Posttraumatic Stress Disorder (PTSD) in patients with accidental injuries.
Detailed Description
Accidental injuries, mostly motor vehicle accident, in civilian population are frequent events. For instance, nearly one-third of injured patients appear to develop trauma-related psychiatric illness and the major diagnoses are post-traumatic stress disorder (PTSD) and depressive disorder. Omega-3 Polyunsaturated Fatty Acid (Omega-3 PUFA) has some evidence of efficacy of treatment in patients with anxiety and mood disorders, but no evidence of preventing anxiety and mood disorders that occur subsequent to accidental injuries. We evaluate efficacy and safety of Omega-3 PUFA for the secondary prevention of Posttraumatic Stress Disorder (PTSD) and related psychiatric illness in patients with accidental injury.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 plus years
- •A native Japanese speaking ability
- •Possibility contact patients with injury in 240 hours, and dosing in oral use
- •Physical and metal status to possible understands scope and contents in the trial and gets informed consent
Exclusion Criteria
- •Clearly irretrievable acute brain parenchyma damage and subdural or subarachnoidal bleeding detected by computed tomography and/or magnetic resonance imaging
- •Cognitive impairment: Mini Mental State Examination < 24
- •Heavy drinker or 100IU/L ≦ γGTP in administration
- •Heavy smoker (over 40 cigarettes per day)
- •History and current suspicion in diagnosis of psychosis and bipolar I disorder
- •Suspicion in diagnosis of alcoholic, substance-related disorder and eating disorder
- •Existence of marked serious symptoms such as suicidal ideation, self-harm behavior, dissociation, status of need rapidly psychiatric treatment
- •Use of anti-epilepsy drug, lithium, ethyl icosapentate and anti-coagulant drug (for example, aspirin, warfarin, etc) within 3 month at regular intervals
- •Use of polyunsaturated fatty acid supplement within 3 month at regular intervals
- •Habit of eating fish over 4 times per week
Outcomes
Primary Outcomes
Total score of Clinician-Administrated PTSD Scale (CAPS)
Time Frame: Three month
Secondary Outcomes
- Incidence of diagnosis of PTSD (including partial PTSD)(Three month, one month)
- Total score of Montgomery Asberg Depression Rating Scale (MADRAS)(Three month, one month)
- Incidence of depression evaluated by Mini-International Neuropsychiatric Interview (MINI)(Three month, one month)
- Autonomic response measured before, during and after script driven imagery and acoustic stimulation(Three month)
- Score of Impact of Event Scale revised (IES-R)(Three month, one month)
- Score of Hospital Anxiety and Depression scale (HADS)(Three month, one month)
- Score of health related Quality of Life scale, SF-36(Three month, one month)
- Score of Conner-Davidson Resilience Scale (CD-RISC)(Three month, one month)
- Brain-derived neurotrophic factor (BDNF) in serum(Three month, one month)
- Number of days of leave taken from the time of injury(Three month)
- Buss-Perry Aggression Questionnaire (BAQ)(Three month, one month, baseline)
- Total score of Clinician-Administrated PTSD Scale (CAPS)(One month)
- DHEA: dehydroepiandrosterone(Three month, one month)
- NPY: neuropeptide Y(Three month, one month)
- IL-1 beta: interleukin 1 beta(Three month, one month)
- IL-6: interleukin 6(Three month, one month)
- TNF alpha: tumor necrosis factor alpha(Three month, one month)
- D-serine(Three month, one month)
- L-serine(Three month, one month)
- DL-serine(Three month, one month)
- Activin(Three month, one month)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 3
Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 StudyTraumaPosttraumatic Stress DisorderNCT00671099Japan Science and Technology Agency110
Unknown
Phase 4
The Effects of Parenteral ω-3 Polyunsaturated Fatty Acid on Postoperative Complications of Patients With Crohn's DiseaseCrohn DiseaseNCT03901937Sir Run Run Shaw Hospital158
Completed
Not Applicable
N-3 Polyunsaturated Fatty Acids in the Prevention and Treatment for IFN-induced DepressionMajor Depressive EpisodeNCT01620502National Science Council, Taiwan230
Terminated
Phase 1
Omega-3 Fatty Acids in Sickle Cell DiseaseSickle Cell DiseaseNCT02947100Robin E. Miller4
Terminated
Phase 3
Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass GraftingIschemic Heart DiseaseAtrial FibrillationNCT01175330Meshalkin Research Institute of Pathology of Circulation39